title: Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Silesian Medical University, Katowice, Poland. Electronic address: ghelbig@o2.pl.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Helbig
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta
keywords: Hypereosinophilic syndromes; Imatinib mesylate; Myeloproliferation; Response